# US 2026/0091093 A1 · Methods Of Treating Plantar Fibromatosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0091093 A1
- Document ID: US20260091093A1
- Status: Published application
- Kind: A1
- Application number: 19/288,249
- Filed: 2025-08-01
- Published: 2026-04-02
- Earliest claimed: 2024-08-02
- Applicants: Endo Biologics Limited
- Inventors: James P. Tursi; Luis A. Ortega; Qinfang Xiang; Saji VIJAYAN; Jeffrey David Lehrman
- Web page: https://patentgrep.com/patent/US20260091093A1

## CPC

- A61K 38/4886: {Metalloendopeptidases (3.4.24), e.g. collagenase}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61P 19/04: for non-specific disorders of the connective tissue
- A61P 35/00: Antineoplastic agents
- C12Y 304/24003: Microbial collagenase (3.4.24.3)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES

## Abstract

Disclosed herein are methods of treating plantar fibromatosis in a subject or a population of subjects.

## Claims

### Claim 1

A method of treating moderate to severe plantar fibromatosis in a subject or a population of subjects, the method comprising:
intralesionally injecting a pharmaceutical formulation comprising collagenase into one or more plantar fibromatosis nodules in one or both of the subject's feet or the population of subjects' feet to thereby treat the plantar fibromatosis, wherein the dose of collagenase administered per nodule comprises about 0.45 mg to about 1.35 mg and the treating comprises:
an improvement from baseline as measured on a patient global impression of change (PGIC)-PF overall scale;
a reduction from baseline as measured on a FFI total composite score;
an improvement from baseline as measured on a subject satisfaction with treatment scale;
or any combination thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the reduction or improvement occurs at Day 57 or earlier.

### Claim 3 (depends on 1)

The method of claim 1, wherein the reduction or improvement is an at least 1 point reduction from baseline or an at least 1 point improvement from baseline.

### Claim 4 (depends on 1)

The method of claim 1, wherein the collagenase comprises collagenase I activity, collagenase II activity, or a mixture of collagenase I activity and collagenase II activity.

### Claim 5 (depends on 1)

The method of claim 1, wherein the subject has an NRS score of ≥5 and <10 prior to treatment.

### Claim 6 (depends on 1)

The method of claim 1, wherein, prior to the injecting, the plantar fibromatosis nodules are hard or firm.

### Claim 7 (depends on 1)

The method of claim 1, wherein, prior to injecting, the subject had an NRS score of less than 10 and did not have moderately firm plantar fibromatosis nodule(s).

### Claim 8 (depends on 1)

The method of claim 1, wherein the collagenase has a concentration of about 0.6 mg/ml to about 2.25 mg/ml.

### Claim 9 (depends on 1)

The method of claim 1, wherein the collagenase has a potency of about 500 SRC units/mg to about 30,000 SRC units/mg.

### Claim 10 (depends on 1)

The method of claim 1, wherein about 5 SRC units to about 180,000 SRC units of collagenase are administered per nodule.

### Claim 11 (depends on 1)

The method of claim 1, wherein the collagenase has a potency of about 10,000 GPA units/mg to about 400,000 GPA units/mg.

### Claim 12 (depends on 1)

The method of claim 1, wherein about 1,000 GPA units to about 2,400,000 GPA units of collagenase are administered per nodule.

### Claim 13

A method of treating moderate to severe plantar fibromatosis in a subject or a population of subjects, the method comprising:
intralesionally injecting a pharmaceutical formulation comprising collagenase into one or more plantar fibromatosis nodules in one or both of the subject's feet or the population of subjects' feet to thereby treat the plantar fibromatosis, wherein the dose of collagenase administered per nodule comprises about 0.6 mg, and the treating comprises:
a reduction from baseline in the FFI Difficulty Subscale score of the FFI;
a reduction from baseline on the FFI Activity Limitation Subscale score;
a reduction from baseline on the FFI Total score;
an improvement from baseline on the PGIS PF Overall score;
an improvement from baseline on the PGIS Difficulty Subscale;
an improvement from baseline on the PGIS Activity Limitation Subscale;
or any combination thereof.

### Claim 14 (depends on 13)

The method of claim 13, wherein the reduction or improvement occurs at Day 85 or earlier.

### Claim 15 (depends on 13)

The method of claim 13, wherein the reduction or improvement is an at least 1 point reduction from baseline or an at least 1 point improvement from baseline.

### Claim 16 (depends on 13)

The method of claim 13, wherein the collagenase comprises collagenase I activity, collagenase II activity, or a mixture of collagenase I activity and collagenase II activity.

### Claim 17 (depends on 13)

The method of claim 13, wherein the subject had an NRS score of 5 to 9 prior to treatment.

### Claim 18 (depends on 13)

The method of claim 13, wherein the subject had an average daily pain (ADP) score on the Pain Intensity NRS of 5 to 9 during the 7 days prior to treatment.

### Claim 19 (depends on 13)

The method of claim 13, wherein, prior to the injecting, the plantar fibromatosis nodules are hard or firm.

### Claim 20 (depends on 13)

The method of claim 13, wherein, prior to injecting, the subject had an NRS score of less than or equal to 9 and did not have moderately firm plantar fibromatosis nodule(s).

### Claim 21 (depends on 13)

The method of claim 13, wherein the plantar fibromatosis nodule is less than or equal to 4 cm in size.

### Claim 22 (depends on 21)

The method of claim 21, comprising administering a single injection of the collagenase to any nodule that is less than 2 cm in size.

### Claim 23 (depends on 21)

The method of claim 21, comprising administering two injections of the collagenase to any nodule that is greater than 2 cm but less than 4 cm in size.

### Claim 24 (depends on 23)

The method of claim 23, wherein each of the two injections comprises 0.3 mg of the collagenase.

### Claim 25 (depends on 13)

The method of claim 13, wherein the collagenase has a concentration of about 0.6 mg/ml to about 2.25 mg/ml.

### Claim 26 (depends on 13)

The method of claim 13, wherein the collagenase has a potency of about 500 SRC units/mg to about 30,000 SRC units/mg.

### Claim 27 (depends on 13)

The method of claim 13, wherein about 5 SRC units to about 180,000 SRC units of collagenase are administered per nodule.

### Claim 28 (depends on 13)

The method of claim 13, wherein the collagenase has a potency of about 10,000 GPA units/mg to about 400,000 GPA units/mg.

### Claim 29 (depends on 13)

The method of claim 13, wherein about 1,000 GPA units to about 2,400,000 GPA units of collagenase are administered per nodule.
